Article
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
The oncologist - 1 Aug 2020
Yang Ching-Yao, Liao Wei-Yu, Ho Chao-Chi, Chen Kuan-Yu, Tsai Tzu-Hsiu, Hsu Chia-Lin, Liu Yi-Nan, Su Kang-Yi, Chang Yih-Leong, Wu Chen-Tu, Liao Bin-Chi, Hsu Chia-Chi, Hsu Wei-Hsun, Lee Jih-Hsiang, Lin Chia-Chi, Shih Jin-Yuan, Yang James Chih-Hsin, Yu Chong-Jen
Abstract excerpt
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression is associated with clinical outcomes of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (ADC) treated with tyrosine kinase inhibitors (TKIs). However, whether PD-L1 expression plays a role in anaplastic lymphoma kinase (ALK)-positive lung ADC is unknown. We aimed to evaluate the impact of PD-L1 in patients with ALK-positive lung ADC...
Topics
Join the communities discussing this publication.